UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology [NASDAQ: UBX] announced that its Compensation Committee has granted a stock-based award to its new Chief Medical Officer, Federico Grossi. The award consists of options to purchase 150,000 shares of UNITY common stock, granted on January 6, 2025. The grant was made under the UNITY 2020 Employment Inducement Incentive Plan, amended in March 2020, which aims to provide incentives for new hires in accordance with Nasdaq Stock Market Rule 5635(c)(4).
UNITY Biotechnology [NASDAQ: UBX] ha annunciato che il suo Comitato per le Compensazioni ha concesso un premio in azioni al suo nuovo Direttore Medico, Federico Grossi. Il premio consiste in opzioni per l'acquisto di 150.000 azioni delle azioni ordinarie di UNITY, concesso il 6 gennaio 2025. La concessione è stata effettuata nell'ambito del piano di incentivazione per l'assunzione del 2020 di UNITY, modificato a marzo 2020, che mira a fornire incentivi per le nuove assunzioni in conformità con la Regola 5635(c)(4) del Nasdaq Stock Market.
UNITY Biotechnology [NASDAQ: UBX] anunció que su Comisión de Compensación ha otorgado un premio basado en acciones a su nuevo Director Médico, Federico Grossi. El premio consiste en opciones para comprar 150,000 acciones de las acciones ordinarias de UNITY, otorgadas el 6 de enero de 2025. La concesión se realizó bajo el Plan de Incentivos de Empleo de Inducción de UNITY 2020, enmendado en marzo de 2020, que tiene como objetivo proporcionar incentivos para nuevas contrataciones de acuerdo con la Regla 5635(c)(4) del Nasdaq Stock Market.
UNITY Biotechnology [NASDAQ: UBX]는 보상위원회가 신임 최고의료책임자인 Federico Grossi에게 주식 기반 보상을 부여했다고 발표했습니다. 이 상은 2025년 1월 6일에 부여된 150,000주의 UNITY 보통주를 구매할 수 있는 옵션으로 구성됩니다. 이 부여는 2020년 3월에 수정된 UNITY 2020 고용 유도 인센티브 계획의 일환으로 이루어졌으며, 이는 신규 채용을 위해 Nasdaq 주식 시장 규칙 5635(c)(4)에 따라 인센티브를 제공하는 것을 목표로 합니다.
UNITY Biotechnology [NASDAQ: UBX] a annoncé que son Comité de Compensation a accordé une récompense en actions à son nouveau Directeur Médical, Federico Grossi. La récompense se compose d'options pour acheter 150 000 actions des actions ordinaires de UNITY, accordées le 6 janvier 2025. L'octroi a été réalisé dans le cadre du Plan d'Incitation à l'Emploi 2020 de UNITY, amendé en mars 2020, qui vise à fournir des incitations pour les nouvelles recrues conformément à la Règle 5635(c)(4) du marché boursier Nasdaq.
UNITY Biotechnology [NASDAQ: UBX] gab bekannt, dass sein Vergütungsausschuss einen aktienbasierten Anreiz an seinen neuen Chief Medical Officer, Federico Grossi, gewährt hat. Der Anreiz besteht aus Optionen zum Kauf von 150.000 Aktien der Stammaktien von UNITY, gewährt am 6. Januar 2025. Die Gewährung erfolgte im Rahmen des UNITY 2020 Employment Inducement Incentive Plans, der im März 2020 geändert wurde und darauf abzielt, Anreize für neue Mitarbeiter gemäß der Nasdaq-Börsenregel 5635(c)(4) bereitzustellen.
- Successful recruitment of new Chief Medical Officer indicating strategic executive team expansion
- Potential shareholder dilution from 150,000 new stock options
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors (the “Board”) granted a stock-based award to a new employee, Federico Grossi, UNITY’s Chief Medical Officer, covering options to purchase 150,000 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine Smith
katherine.smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
How many stock options were granted to UBX's new Chief Medical Officer in January 2025?
What is the purpose of UBX's 2020 Employment Inducement Incentive Plan?
Who is the new Chief Medical Officer at UNITY Biotechnology (UBX)?
When did UBX's Board approve the Employment Inducement Incentive Plan?
